stockrowPulse Biosciences, Inc
PLSE Healthcare Medical Instruments & Supplies
Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022.
- Revenue
- +359.3%
- EPS
- −10.3%
- Free cash flow
- −1,180.5%
Quarter to September 2026, against a year earlier
Follow PLSE
Alert me
Pulse Biosciences, Inc (PLSE) Operating cash flow
Pulse Biosciences, Inc's operating cash flow for fiscal 2025 was −$54.1M, compared with −$36.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$63.3M. Over the past ten years it has ranged from −$54.1M (fiscal 2025) to −$3.3M (fiscal 2015) — the current reading is the lowest in ten years. Pulse Biosciences, Inc ranks 49th of 51 Medical Instruments & Supplies companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$54.1M | — |
| FY2024 | −$36.3M | — |
| FY2023 | −$33.0M | — |
| FY2022 | −$47.0M | — |
| FY2021 | −$54.1M | — |
| FY2020 | −$35.4M | — |
| FY2019 | −$34.2M | — |
| FY2018 | −$23.9M | — |
| FY2017 | −$11.1M | — |
| FY2016 | −$8.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$15.3M | — |
| Jun 2026 | −$18.7M | — |
| Mar 2026 | −$14.6M | — |
| Dec 2025 | −$14.8M | — |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| NVST Envista Holdings Corporation compare | $301.8M |
| STVN Stevanato Group S.p.A. compare | $289.2M |
| ICUI ICU Medical, Inc. compare | $279.2M |
| MMSI Merit Medical Systems, Inc. compare | $273.7M |
| TFX Teleflex Incorporated compare | $129.3M |
| WRBY Warby Parker Inc. compare | $102.1M |
| ATRC AtriCure, Inc. compare | $68.5M |
| PLSE Pulse Biosciences, Inc | −$63.3M |
| MMED MiniMed Group, Inc. compare | −$134.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on PLSE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement